Focus: Rubedo Life Sciences is a publicly-traded biotech focused on age-related drug discovery, leveraging senescence-targeting mechanisms to address age-related diseases. The company operates as a mid-cap biotech with early-stage clinical programs.
Profile data last refreshed 19h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Rubedo Life Sciences to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Rubedo Life Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Rubedo Life Sciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth - Business Wire
Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth Business Wire
Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness - drugdiscoverytrends.com
Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness drugdiscoverytrends.com
Rubedo reports early clinical signal for senotherapeutic drug - Longevity.Technology
Rubedo reports early clinical signal for senotherapeutic drug Longevity.Technology
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
Uncovering senescent fibroblast heterogeneity connects DNA damage response to idiopathic pulmonary fibrosis.
Advancing senescence translation through the Senotherapeutics Biomarker Consortium.
Showing 5 of 7 publications